A Health Economics Response to the Review of the Liverpool Care Pathway by Kinghorn, Philip & Coast, Joanna
 
 
University of Birmingham
A Health Economics Response to the Review of the
Liverpool Care Pathway
Kinghorn, Philip; Coast, Joanna
DOI:
10.1089/jpm.2013.0464
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Kinghorn, P & Coast, J 2013, 'A Health Economics Response to the Review of the Liverpool Care Pathway',
Journal of Palliative Medicine, vol. 16, no. 12, pp. 1614-1616. https://doi.org/10.1089/jpm.2013.0464
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/jpm.2013.0464
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1 
 
A health economics response to the review of the Liverpool Care Pathway 
 
Philip B Kinghorn1, Joanna Coast1 
 
1Health Economics Unit, School of Health & Population Sciences, Public Health 
Building, University of Birmingham, Birmingham, B15 2TT  
 
Correspondence to: p.kinghorn@bham.ac.uk 
 
Abstract 
 
Background: In 2011 the Palliative Care Funding Review highlighted concerns about the 
funding, provision and quality of care at the end of life.  Two years on, an Independent 
Review of the Liverpool Care Pathway – prompted by a storm of negative media 
coverage – has raised concerns around a lack of: funding, availability of support for the 
dying and their relatives, and patient centred care.  There are recommendations to 
increase funding through a national tariff for palliative care services, address 
inconsistencies, and replace the Liverpool Care Pathway with individual end of life care 
plans. 
Objective: This paper explores the economic implications of the review’s 
recommendations and links these to inadequacies with the current economic framework 
currently recommended for use in the UK by the National Institute for Health and Care 
Excellence, before highlighting aspects of ongoing research aimed at addressing these 
inadequacies.   
Methods: As well as the published report ‘More Care, Less Pathway’, we draw upon 
preliminary qualitative evidence from 19 semi-structured interviews conducted with 
academics specialising in economics and/or end of life care. 
Conclusions: Whilst there is a need for increased funding in the short-term (highlighted 
in recent reviews), increasing funding to services which have little evidence base 
appears to be an irresponsible long-term strategy.  Hence there should also be 
increased investment in research and increased emphasis in particular on developing 
economic tools to evaluate services.    
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Background 
 
The Palliative Care Funding Review (published in 2011) highlighted the importance of 
ensuring 24/7 access to services, integration of services across health and social care, a 
reduction in inequalities, , and a simplified/standardised funding model1.  Two years on 
and attention has turned to Baroness Neuberger’s review of the Liverpool Care Pathway 
(LCP).  The LCP relates to the last two to three days of a patient’s life, and so this latest 
review is somewhat narrower in its focus, but (as can be seen from Table 1) there are 
striking similarities nonetheless.   
 
[Insert Table 1 here] 
 
This paper highlights the economic implications of the LCP review (in the context of 
broader issues identified through interviews with stakeholders), sets out reasons why the 
most widely used health economics framework is ill-equipped to deal with the 
complexities of end of life care, and introduces work which aims to expand the health 
economist’s toolkit. 
 
As part of the European Research Council funded Economics of End of Life Care 
(EconEndLife) project, 19 semi-structured interviews have been conducted to date with 
academics representing a number of disciplines (health economics, health psychology, 
nursing, clinical and allied health professions).  University ethics approval was obtained 
for the interviews, which have been transcribed and analysed using constant 
comparative analysis.   
 
 
Economic issues around end of life care  
 
Healthcare is an economic good in the sense that delivering more of one type of care 
(from a fixed budget) displaces care elsewhere in the system.  To inform policy-makers 
about resource allocation decisions, health economists in the UK and other countries 
use quality-adjusted life years (QALYs), which incorporate length of life and societal 
values reflecting health-related quality of life.  The QALY is a widely used practical tool, 
but has a number of limitations which make it particularly restrictive in the context of end 
of life care. We match the limitations of the QALY to recommendations from the LCP 
review. 
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Perspective: 
 
The LCP review states that clinicians bear some responsibility for relatives and carers as 
well as patients2, p9.  As well as recommending that funding be made available to 
improve accessibility of services to support relatives caring for patients at home, the 
review recommends that greater attention be given to the welfare and privacy of 
relatives in the period immediately after death.  The stakeholders we interviewed also 
acknowledged the hugely important contribution of and need to support unpaid carers. 
 
...whether the carer felt well supported... IS an end of life care outcome because 
you see the patient and the family as an indivisible unit.  (ID8, Nursing) 
 
However, in line with the National Institute for Health and Care Excellence (NICE) 
reference case, health interventions are currently evaluated only with respect to costs 
incurred through providing health or social care services and changes in patient 
outcomes3.  The emotional, psychological or even health impact on family and carers 
would not usually be captured or included, suggesting that no priority would be given to 
funding services with these objectives. 
 
Economists are only in the early stages of suggesting how non-patient outcomes would 
be measured or included conceptually in their analyses. 
 
Non-health outcomes  
 
The LCP review makes reference to a person’s dignity and to clinicians being mindful of 
the emotional, social and spiritual needs of dying patients2.  Just as the LCP review 
places emphasis on the importance of non-health outcomes, so did the stakeholders 
interviewed as part of the EconEndLife study, with common examples of broader 
outcomes being social aspects/relationships, spirituality/meaning making, and 
accomplishing goals.  Other suggestions included dignity and identity.  If these 
outcomes are to carry weight in economic evaluation then they need to be incorporated 
into the quality (‘Q’) element of the QALY. 
 
The Q in QALYs is typically assessed using generic health status classification systems, 
such as the EQ-5D (recommended by NICE in the UK3), which assesses health in terms 
of: anxiety and depression; pain and discomfort; usual activities; mobility; and self-care4.  
Whilst economic instruments such as the EQ-5D may be too limited in their focus (failing 
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to capture aspects such as spirituality), condition-specific measures currently available 
are not helpful for economic evaluation as they are too long to easily attach values to, 
and/or are insufficiently generic (for example focusing on particular groups of patients at 
end of life)5. 
 
In our interviews, those favourable to the QALY felt that restricting the focus of economic 
evaluation to health alone is appropriate.   Some felt that the use of QALYs in-line with 
the NICE reference case is as appropriate in the context of end of life care as it is for 
other temporary health states where the focus is on maximising health (for example by 
relieving pain) rather than extending life.   
 
...I don’t think there’s anything particular about end of life care that makes the 
EQ-5D strong or weak ...[T]he driving force is always going to be around how we 
extend life and improve quality of life.  (ID12, Health Economist) 
 
Others expressed the view that the inevitability of declining health and importance to the 
patient and family of broader outcomes makes end of life care different and the use of 
the QALY, as it is typically operationalised, problematic.   
 
...inevitably they’re going to get sicker as they approach death so if you’re using 
as an outcome measure how sick they are, all of our studies are going to fail 
(ID4, Health Psychologist) 
 
Some health economists suggested the QALY framework, despite having the potential 
for broad use, is too restrictive in its current form.  Stakeholders also raised concerns 
about the ‘LY’ element of QALYs, an issue which has been debated elsewhere6 7. 
 
Generally, a fundamental question to address is whether society deems the 
maximisation of health to be the sole legitimate objective of the health system.  If the 
objectives of services funded from a fixed healthcare budget are to include broader 
outcomes and processes how these are to be traded off against health gain?   
 
 
(Lack of) a national tariff for palliative care services; the tip of the iceberg 
 
Both reviews recommend the establishment of a national Payment by Results (PbR) 
tariff for palliative care services.  PbR is a “payment system in England under which 
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commissioners pay healthcare providers for each patient seen or treated, taking into 
account the complexity of the patient’s healthcare needs.”8  Guidance by the 
Department of Health states that: “Not all services ...have a national tariff, for a number 
of reasons, including the quality of available costing and activity data”9, P15.  Lack of a 
mandatory tariff has meant some Trusts operating palliative care services as loss 
making activity1.  The lack of available data may arise in part from inconsistency in the 
delivery of palliative care services and complexity in the funding model, as highlighted by 
the Funding Review.  We would expect to see a link between the provision of healthcare 
services and available evidence relating to clinical and cost-effectiveness, but the 
development of an evidence base in the context of end of life care is hindered by the 
practical and ethical difficulties of conducting trials, a perceived lack of health economics 
interest, and, as some stakeholders suggested in our interviews, by a lack of funding: 
 
...there’s... different models of care in place, some of which have been tested and 
others not... we’re still a long way off having good investment in research in 
palliative care.  Let alone health economic evaluations in palliative care. (ID14, 
Clinical) 
 
Whilst there is clearly a short-term need to increase funding for end of life care, pumping 
funding into services which have no evidence base seems to be an irresponsible long-
term strategy.  Increased funding for services should be matched by investment in 
research and, given the difficulty in conducting research in this context, there is a need 
for innovative methodology. 
 
 
Rising to the challenge 
 
There are important methodological questions around the economic evaluation of end of 
life care.  What should be measured at end of life – for patients and the people close to 
them?  Who should count in an evaluation?  How should the benefits of end of life care 
be valued?  Who should do this valuation?  And how should the results be brought into 
decision making?  These challenging, but important, questions are currently being 
tackled in the EconEndLife programme of research, the first output of which is a new 
measure developed to evaluate palliative and supportive care for patients, the ICECAP 
Supportive Care Measure (ICECAP-SCM). The instrument measures patients’ wellbeing 
in terms of an individual’s ‘capability’ (a term referring to ability, rather than achieved 
outcomes)10. The descriptive system was developed through talking to people about 
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what is important to them at the end of life, and covers seven attributes: Autonomy 
(having a say); Love (being with people who care about you); Physical suffering; 
Emotional suffering; Dignity; Support (having help and support); Preparation.  Values for 
use of the measure in economic evaluation are currently being developed.  Attributes 
capture issues important at the end of life, not or only partially captured by measures of 
health functioning.  ICECAP-SCM will enable inclusion of more meaningful information 
within economic evaluations. 
 
These methodological developments will provide a way forward for the evaluation of end 
of life care.  Ultimately, however, the more fundamental question of whether the health 
budget should be spent on providing care at the end of life, even if health gain is not an 
outcome of that care, must be explicitly tackled.  As long as health gain is the only 
valued outcome for organisations such as NICE, care for patients and their families at 
the end of life will never have the priority that recent reviews suggest it should have. 
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